Asma Shaukat, MD, Professor of Medicine at NYU Grossman School of Medicine and outgoing Chair of the Clinical Practice Section for the AGA Council, discussed 13-year Nordic trial findings showing reduced colorectal cancer incidence with colonoscopy screening, along with emerging data on GLP-1 therapies in fatty liver disease and cirrhosis. Bruce Sands, MD, Chief of Gastroenterology and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, presented findings from the DUET-CD study evaluating combination therapy in Crohn’s disease.

Dr. Luke Laughlin (Preventive Cardiologist, Cleveland Clinic) presented the Cardinal trial at ACC 2026, where Tonlamarsen, an investigational antisense oligonucleotide, reduced angiotensinogen by 67% with ongoing dosing and maintained 23% suppression after a single dose. Despite biochemical differences, both groups achieved similar ~7 mmHg systolic BP reductions, suggesting BP lags behind RAAS suppression. The upcoming Cardinal-ASH study will target acute severe hypertension patients to further evaluate its impact.